Loading...

FHTX FOGHORN THERAPEUTICS INC Earnings Reports 8-K Filing

FGHR

FHTX

FOGHORN THERAPEUTICS INC

(FHTX)

2023 8-K

Management Change

Investor Presentation

Financial Update

Pipeline Updates

Investor Presentation

Financial Statements

Management Changes

Financial Statements

Clinical Trials

Investor Presentation

Stock Sale Amendment

Financial Results

Investor Presentation

Audit Committee Notice

Preliminary Results

Director Resignation

Product Discontinuation

Financial Results

Trial Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Public Offering

Financial Results Announcement

Appointment of CFO

Conference Call and Webcast

Financial Results Announcement

Appointment of CFO

Press Release and Investor ...

Departure of Chief Financia...

Financial Results Announcement

Termination of Agreement

Management Changes

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Update on FHD-609 Program

Financial Results and Bylaw...

Press Release and Investor ...

External Links:

Foghorn Therapeutics provides an update on its FHD-609 program in synovial sarcoma and SMARCB1-deleted tumors, announcing completion of dose escalation and identification of maximum tolerated dose, but pausing enrollment due to a grade 4 QTc prolongation event in a patient.

AI Assistant

FOGHORN THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.